Title: A Network Meta-analysis of Different Interventional Treatment Strategies for
Unresectable Hepatocellular Carcinoma
Version: 2 Date: 26 Mar 2025
Reviewer's report:
1.Although the study mentions that the heterogeneity test results show no significant
heterogeneity (I² < 50%), it does not delve into the potential sources of heterogeneity. It is
suggested that the discussion section should further analyze factors that may influence the
therapeutic effect, such as patient baseline characteristics and specific differences in treatment
protocols, to enhance the interpretability of the study results.
2. Due to the study being restricted to RCTs and PSM cohort studies, the sample size is relatively
small. It is recommended that future multicenter, large-scale clinical trials be conducted to
further validate the reliability of the study conclusions.
3.There is only one randomized controlled trial of HAIC in the study, and the reliability of its
results may be limited. It is suggested that the discussion section should provide a more cautious
interpretation of the efficacy and safety of HAIC as a standalone treatment, and emphasize the
need for more high-quality studies in the future to verify its clinical application value.
Title: A Network Meta-analysis of Different Interventional Treatment Strategies for
Unresectable Hepatocellular Carcinoma
Version: 2 Date: 26 Mar 2025
Reviewer's report:
1.Although the study mentions that the heterogeneity test results show no significant
heterogeneity (I² < 50%), it does not delve into the potential sources of heterogeneity. It is
suggested that the discussion section should further analyze factors that may influence the
therapeutic effect, such as patient baseline characteristics and specific differences in treatment
protocols, to enhance the interpretability of the study results.
2. Due to the study being restricted to RCTs and PSM cohort studies, the sample size is relatively
small. It is recommended that future multicenter, large-scale clinical trials be conducted to
further validate the reliability of the study conclusions.
3.There is only one randomized controlled trial of HAIC in the study, and the reliability of its
results may be limited. It is suggested that the discussion section should provide a more cautious
interpretation of the efficacy and safety of HAIC as a standalone treatment, and emphasize the
need for more high-quality studies in the future to verify its clinical application value.
Please review this paper.
user
Title: A Network Meta-analysis of Different Interventional Treatment Strategies for
Unresectable Hepatocellular Carcinoma
Version: 2 Date: 26 Mar 2025
Reviewer's report:
1.Although the study mentions that the heterogeneity test results show no significant
heterogeneity (I² < 50%), it does not delve into the potential sources of heterogeneity. It is
suggested that the discussion section should further analyze factors that may influence the
therapeutic effect, such as patient baseline characteristics and specific differences in treatment
protocols, to enhance the interpretability of the study results.
2. Due to the study being restricted to RCTs and PSM cohort studies, the sample size is relatively
small. It is recommended that future multicenter, large-scale clinical trials be conducted to
further validate the reliability of the study conclusions.
3.There is only one randomized controlled trial of HAIC in the study, and the reliability of its
results may be limited. It is suggested that the discussion section should provide a more cautious
interpretation of the efficacy and safety of HAIC as a standalone treatment, and emphasize the
need for more high-quality studies in the future to verify its clinical application value.
assistant